Opthea Limited (ASX:OPT)
Australia
· Delayed Price · Currency is AUD | Market Cap | 738.77M |
| Revenue (ttm) | 336.08K |
| Net Income (ttm) | -403.04M |
| Shares Out | 1.23B |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,141,489 |
| Average Volume | 310,447 |
| Open | 0.6050 |
| Previous Close | 0.6000 |
| Day's Range | 0.5950 - 0.6150 |
| 52-Week Range | 0.3350 - 1.1650 |
| Beta | 1.59 |
| RSI | 22.25 |
| Earnings Date | May 28, 2025 |
About Opthea
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit V... [Read more]
Financial Performance
In 2024, Opthea's revenue was $261,859, a decrease of -32.03% compared to the previous year's $385,275. Losses were -$220.24 million, 54.5% more than in 2023.
Financial numbers in USD Financial StatementsNews
ASX 200 LIVE: Trump tariffs; sharemarket drops 1pc on Wednesday, iron ore slumps; US equities fall on escalating US-China trade war
Shares drop, US closes in on 104pc China tariff; RBNZ signals scope for further cuts; oil below $US61; iron ore at seven-month low; Regal’s $540m Opthea blow.
Phil King’s Regal writes Opthea to zero and backs off risky bets
The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ensure it does not occur again”.
Opthea (OPT) Halts Key Trials Following Disappointing Results
Opthea (OPT) Halts Key Trials Following Disappointing Results
Opthea in active talks with funders after second trial fails
The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye disease treatment had failed.
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
The clinical trial result from hell has biotech investors on edge
From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, big fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.
Pengana freezes fund redemptions as it braces for big Opthea loss
The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has warned it could be insolvent.
ASX 200 LIVE: Donald Trump eyeing copper tariffs; February CPI below forecasts; sharemarket rises.
ASX rises as banks, miners rally; CPI below forecast; Hearts & Minds slashes value of Opthea; TPG fined $75,000; Paladin sinks, retracts guidance.
Regal’s listed funds slash value of biotech Opthea by two-thirds
The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It is the company’s largest investor.
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
On Monday, Opthea Limited (NASDAQ: OPT) released results from its global Phase 3 clinical trial COAST in patients with wet age-related macular degeneration (wet AMD) . The trial evaluated the efficac...
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play that could become insolvent after a poor medical result.
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
ASX 200 LIVE: UBS upgrades FMG; OPT in crisis talks after drug trial fails, shares suspended; sharemarket falls.
Shares fall; UBS neutral on Fortescue; Opthea drug trial spurs crisis talks; MinRes resumes Onslow haulage; James Hardie, Helia drop; $A, gold lower.
It’s Phil King’s Regal against the shorts at biotech play Opthea
The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial clinical trial, shorts are rising.
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Februar...
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia an...
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J.,...
Opthea's Wet AMD Program Featured at Ophthalmology Events
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEW...
Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...